Commentary Article

iMedPub Journals
www.imedpub.com

Journal of Obesity & Eating Disorders
ISSN 2471-8203

2025
Vol.11 No.2:209

Long-Term Effects of Adipose Tissue-Derived Stem Cells (ADSCs) in the Skin Amyloidosis

Shiganammi Yura*

Department of Neurology, Nagitsuji Hospital, Yamashina, Kyoto, Japan

***Corresponding author:** Shiganammi Yura, Department of Neurology, Nagitsuji Hospital, Yamashina, Kyoto, Japan;E-mail:yura@gmail.com

Received date: December 17, 2024, Manuscript No. IPJOED-24-20178; **Editor assigned date:** December 20, 2024, PreQC No. IPJOED-24-20178 (PQ); **Reviewed date:** January 06, 2025, QC No. IPJOED-24-20178; **Revised date:** April 17, 2025, Manuscript No. IPJOED-24-20178 (R); **Published date:** April 24, 2025, DOI: 10.36648/2471-8203.11.2.209

Citation: Yura S (2025) Long-Term Effects of Adipose Tissue-Derived Stem Cells (ADSCs) in the Skin Amyloidosis. J Obes Eat Disord Vol:11 No:2

Description

Amyloidosis refers to a group of diseases characterized by the deposition of abnormal amyloid proteins in tissues and organs, leading to progressive dysfunction. Skin amyloidosis is a localized form of this condition where amyloid fibrils accumulate in the dermis, often leading to disfiguring lesions and potential complications in the affected tissues. In recent years, Adipose Tissue-Derived Stem Cells (ADSCs) have emerged as a promising therapeutic approach for a variety of conditions, including those that involve tissue degeneration and fibrosis. Their potential role in skin amyloidosis has generated significant interest due to their regenerative properties and ability to modulate inflammation, fibrosis, and tissue repair.

ADSCs also secrete a wide array of bioactive factors that influence tissue repair and modulate immune responses, making them valuable for treating chronic inflammatory conditions and degenerative diseases. Moreover, their ability to home to sites of injury and inflammation further enhances their potential therapeutic benefits.

Pathophysiology of skin amyloidosis

Amyloidosis, in general, is caused by the misfolding of proteins into insoluble fibrils that deposit in tissues. The most common form of skin amyloidosis is primary localized cutaneous amyloidosis, which is often inherited or idiopathic in nature. These amyloid deposits can lead to skin thickening, itching, and the formation of hyperpigmented plaques. The presence of amyloid in the skin may also cause inflammatory responses and fibrosis, resulting in the loss of normal skin structure and function. Although skin amyloidosis primarily affects the skin, it can also be a part of systemic amyloidosis, affecting other organs such as the kidneys, heart, and liver.

ADSCs have the ability to differentiate into multiple cell types, including those that make up the skin, such as keratinocytes, fibroblasts, and endothelial cells. Through this regenerative capacity, ADSCs can help repair damaged skin tissues, restore skin integrity, and improve the aesthetic appearance of the skin. Additionally, their paracrine effects (the release of growth factors and cytokines) further enhance the regenerative environment, potentially reversing some of the damage caused by amyloid deposits.

ADSCs play an important role in promoting angiogenesis, the formation of new blood vessels. In skin amyloidosis, impaired blood flow to the affected tissues can exacerbate the damage. ADSCs stimulate angiogenesis through the secretion of angiogenic factors, improving tissue perfusion and promoting wound healing. Enhanced blood supply to the affected skin can support the regeneration of healthy tissue and reduce the impact of amyloid deposits.

Chronic inflammatory conditions such as skin amyloidosis often involve dysregulated immune responses. ADSCs have been shown to modulate the immune system by reducing the activation of pro-inflammatory immune cells like T-cells and macrophages, and promoting the activity of anti-inflammatory immune cells. By modifying the immune response, ADSCs could potentially prevent further progression of amyloid deposits and aid in the resolution of ongoing skin inflammation.

Mechanisms of ADSC action in skin amyloidosis

The therapeutic potential of ADSCs in treating skin amyloidosis lies in their regenerative properties, particularly their ability to reduce fibrosis, promote tissue repair, and modulate immune responses. Research into ADSC therapy for amyloidosis, especially skin amyloidosis, suggests several mechanisms through which these cells could exert their effects:

Amyloidosis is often associated with chronic inflammation. ADSCs secrete various cytokines and growth factors that have anti-inflammatory effects. These secretions can downregulate pro-inflammatory cytokines and promote the resolution of inflammation. By reducing inflammation in the skin, ADSCs may prevent further amyloid deposition and mitigate the adverse effects of amyloid deposits on the skin tissue.

While the immediate effects of ADSC therapy are promising, understanding the long-term effects is critical for assessing its potential as a sustainable treatment option for skin amyloidosis. In general, ADSC therapy for skin conditions has shown positive results over extended periods, but several factors must be considered.

Sustained tissue repair is One of the expected long-term outcomes of ADSC therapy is continued tissue repair and regeneration. As ADSCs have the ability to promote skin remodeling, the treated area may exhibit long-lasting improvement in terms of elasticity, strength, and appearance.

However, the persistence of amyloid deposits and ongoing skin damage may limit the extent of healing, requiring repeated treatments. Skin amyloidosis has a tendency to recur, especially in cases where the underlying cause of amyloid deposition is not addressed.

ADSCs may help reduce the recurrence of amyloid deposits by modifying the local environment to be less conducive to amyloid fibril formation. However, the long-term success of ADSC therapy will depend on the underlying disease process, and repeated treatments may be necessary to prevent relapse.